Literature DB >> 17971664

A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia.

A H Simonsen1, J McGuire, V N Podust, N-O Hagnelius, T K Nilsson, E Kapaki, D Vassilopoulos, G Waldemar.   

Abstract

BACKGROUND: An early and accurate diagnosis of Alzheimer's disease (AD) is important in order to initiate symptomatic treatment with currently approved drugs and will be of even greater importance with the advent of disease-modifying compounds.
METHODS: Protein profiles of human cerebrospinal fluid samples from patients with AD (n = 85), frontotemporal dementia (n = 20), and healthy controls (n = 32) were analyzed by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to verify previously discovered biomarkers.
RESULTS: We verified 15 protein biomarkers that were able to differentiate between AD and controls, and 7 of these 15 markers also differentiated AD from FTD.
CONCLUSION: A panel of cerebrospinal fluid protein markers was verified by a proteomics technology which may potentially improve the accuracy of the AD diagnosis. (c) 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17971664     DOI: 10.1159/000110576

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  32 in total

1.  Biomarkers of basic activities of daily living in Alzheimer's disease.

Authors:  James R Hall; Leigh A Johnson; Robert C Barber; Hoa T Vo; A Scott Winter; Sid E O'Bryant
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 2.  Proteomics of human neurodegenerative diseases.

Authors:  Jing Zhang; C Dirk Keene; Catherine Pan; Kathleen S Montine; Thomas J Montine
Journal:  J Neuropathol Exp Neurol       Date:  2008-10       Impact factor: 3.685

Review 3.  Biomarkers for Alzheimer disease in cerebrospinal fluid, urine, and blood.

Authors:  Anders Lönneborg
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

Review 4.  The extended granin family: structure, function, and biomedical implications.

Authors:  Alessandro Bartolomucci; Roberta Possenti; Sushil K Mahata; Reiner Fischer-Colbrie; Y Peng Loh; Stephen R J Salton
Journal:  Endocr Rev       Date:  2011-08-23       Impact factor: 19.871

5.  Fluid Biomarkers of Frontotemporal Lobar Degeneration.

Authors:  Emma L van der Ende; John C van Swieten
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  Proteomic analysis of endoscopically (endoscopic pancreatic function test) collected gastroduodenal fluid using in-gel tryptic digestion followed by LC-MS/MS.

Authors:  Joao A Paulo; Linda S Lee; Bechien Wu; Kathryn Repas; Peter A Banks; Darwin L Conwell; Hanno Steen
Journal:  Proteomics Clin Appl       Date:  2010-09       Impact factor: 3.494

7.  Label-free quantitative LC-MS proteomics of Alzheimer's disease and normally aged human brains.

Authors:  Victor P Andreev; Vladislav A Petyuk; Heather M Brewer; Yuliya V Karpievitch; Fang Xie; Jennifer Clarke; David Camp; Richard D Smith; Andrew P Lieberman; Roger L Albin; Zafar Nawaz; Jimmy El Hokayem; Amanda J Myers
Journal:  J Proteome Res       Date:  2012-05-17       Impact factor: 4.466

Review 8.  Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?

Authors:  Robert E Becker; Nigel H Greig; Ezio Giacobini
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

Review 9.  Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments.

Authors:  Simone Lista; Henrik Zetterberg; Bruno Dubois; Kaj Blennow; Harald Hampel
Journal:  J Neurol       Date:  2014-05-08       Impact factor: 4.849

Review 10.  Glycoproteomics in neurodegenerative diseases.

Authors:  Hyejin Hwang; Jianpeng Zhang; Kathryn A Chung; James B Leverenz; Cyrus P Zabetian; Elaine R Peskind; Joseph Jankovic; Zhen Su; Aneeka M Hancock; Catherine Pan; Thomas J Montine; Sheng Pan; John Nutt; Roger Albin; Marla Gearing; Richard P Beyer; Min Shi; Jing Zhang
Journal:  Mass Spectrom Rev       Date:  2010 Jan-Feb       Impact factor: 10.946

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.